2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
22
Active not recruiting
9
Withdrawn
5
Terminated
3
No longer available
2
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Carboplatin
127
Cisplatin
125
Drug Therapy
116
Bevacizumab
102
Capecitabine
100
Oxaliplatin
99
Radiotherapy
97
Gemcitabine
87
tislelizumab
86
Paclitaxel
86
Cyclophosphamide
85
pembrolizumab
77
Specimen Handling
77
toripalimab
70
Magnetic Resonance Spectroscopy
63
Injections
63
Fluorouracil
63
sintilimab
58
Surgical Procedures, Operative
58
anlotinib
53
Docetaxel
52
130-nm albumin-bound paclitaxel
51
fludarabine
47
Standard of Care
45
Pemetrexed
45
Immune Checkpoint Inhibitors
45
Blood Specimen Collection
43
venetoclax
42
Leucovorin
42
lenvatinib
41
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
navitoclax
×
Clear all
NCT05054465
2021-09-23
ITALLI001
Israeli Medical Association
Phase 1/2
Not yet recruiting
48 enrolled